<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR891128-0071 </DOCNO><DOCID>fr.11-28-89.f2.A1070</DOCID><TEXT><ITAG tagnum="69"><ITAG tagnum="18">Food and Drug Administration</ITAG><ITAG tagnum="41">[Docket No. 89N-0433]</ITAG><ITAG tagnum="56">Biological Products; In Vitro Tests To Detect Antibodies to the HumanImmunodeficiency Virus, Type 1; Points to Consider; Request for Comments,Data, and Recommendations; Availability</ITAG><ITAG tagnum="10"><T2>AGENCY: </T2>Food and Drug Administration, HHS.</ITAG><ITAG tagnum="10"><T2>ACTION: </T2>Notice.</ITAG><ITAG tagnum="10"><T2>SUMMARY: </T2>The Food and Drug Administration (FDA) is announcingthe availability of a draft document entitled ``Points to Consider in theManufacture and Clinical Evaluation of <T3>In Vitro </T3>Tests to Detect Antibodies to the Human ImmunodeficiencyVirus; Type 1 (1989).''FDA is also requesting comments, data, and recommendations from the publicon this document. The agency eventually may develop this document intoa guideline or regulations to help ensure the safety, purity, potency,and effectiveness of biological products, new drugs, or other productsregulated under the Federal Food, Drug, and Cosmetic Act or under the PublicHealth Service Act.</ITAG><ITAG tagnum="10"><T2>DATE: </T2>Comments by January 29, 1990.</ITAG><ITAG tagnum="10"><T2>ADDRESSES: </T2>Submit written requests for single copies of the draftdocument to the Congressional and Public Affairs Staff (HFB-140), Foodand Drug Administration, Park Bldg., room 158, 5600 Fishers Lane, Rockville,MD 20857. Send two self-addressed adhesive labels to assist that officein processing your request. Submit written comments on the draft documentto the Dockets Management Branch (HFA-305), Food and Drug Administration,room 4-62, 5600 Fishers Lane, Rockville, MD 20857. Requests and commentsshould be identified with the docket number found in brackets in the headingof this document. Copies of the draft document and received comments areavailable for public examination in the Dockets Management Branch between9 a.m. and 4 p.m., Monday through Friday.</ITAG><ITAG tagnum="10"><T2>FOR FURTHER INFORMATION CONTACT: </T2>Karen L. Goldenthal, Center forBiologics Evaluation and Research (HFB-230), Food and Drug Administration,8800 Rockville Pike, Bethesda, MD 20892, 301-443-4864.</ITAG><ITAG tagnum="10"><T2>SUPPLEMENTARY INFORMATION: </T2>As a result of the recognition of acquiredimmunodeficiency syndrome (AIDS) and the identification of the etiologicagent, human immunodeficiency virus type 1, (HTV-1), there has been extensiveinterest in the development of in vitro diagnostic tests for detectingevidence of infection with the virus. FDA's Center for Biologics Evaluationand Research has developed a draft document concerning these products,entitled ``Points to Consider in the Manufacture and Clinical Evaluationof <T3>In Vitro </T3>Tests to Detect Antibodies to the Human ImmunodeficiencyVirus, Type 1 (1989).'' FDA is issuing this document to provide usefulguidance to manufacturers engaged in the production and clinical evaluationof such in vitro test kits. FDA is announcing availability of the draftdocument and is inviting public comment.FDA may develop this document into a guideline under 21 CFR 10.90(b)(1)or into regulations as needed to help ensure the safety, purity, potency,and effectiveness of biological products, new drugs, or other productsregulated under the Federal Food, Drug, and Cosmetic Act or under the PublicHealth Service Act. Because these new technologies are changing and improvingconstantly, FDA may revise the draft document several times and place therevisions on display at the Dockets Management Branch (address above).<ITAG tagnum="21">Dated: November 20, 1989.</ITAG><ITAG tagnum="6">Ronald G. Chesemore,</ITAG><ITAG tagnum="4">Acting Associate Commissioner for Regulatory Affairs.</ITAG><ITAG tagnum="40">[FR Doc. 89-27807 Filed 11-27-89; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4160-01-MZ</ITAG></ITAG></ITAG></TEXT></DOC>